Gilead's Livdelzi shows sustained liver marker improvement in PBC study

May 27, 2026 2:00 AM

Gilead Sciences Inc. (NASDAQ: GILD) reported interim data from its Phase 3 ASSURE study showing that Livdelzi (seladelpar) achieved sustained ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found